DrugCite
Search

TARCEVA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Tarceva Adverse Events Reported to the FDA Over Time

How are Tarceva adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tarceva, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tarceva is flagged as the suspect drug causing the adverse event.

Most Common Tarceva Adverse Events Reported to the FDA

What are the most common Tarceva adverse events reported to the FDA?

Death
1361 (6.75%)
Rash
835 (4.14%)
Diarrhoea
783 (3.88%)
Nausea
315 (1.56%)
Dyspnoea
303 (1.5%)
Fatigue
283 (1.4%)
Disease Progression
223 (1.11%)
Vomiting
214 (1.06%)
Dehydration
210 (1.04%)
Asthenia
190 (.94%)
Pyrexia
186 (.92%)
Show More Show More
Malignant Neoplasm Progression
180 (.89%)
Haemoptysis
175 (.87%)
Pneumonia
175 (.87%)
Decreased Appetite
172 (.85%)
Weight Decreased
168 (.83%)
Cough
149 (.74%)
Interstitial Lung Disease
143 (.71%)
Dry Skin
142 (.7%)
Respiratory Failure
141 (.7%)
Pulmonary Embolism
127 (.63%)
Pleural Effusion
125 (.62%)
Anaemia
120 (.59%)
Haemoglobin Decreased
107 (.53%)
Thrombocytopenia
98 (.49%)
Stomatitis
96 (.48%)
Dermatitis Acneiform
92 (.46%)
Pruritus
91 (.45%)
Dysphagia
89 (.44%)
Neoplasm Malignant
89 (.44%)
General Physical Health Deteriorati...
87 (.43%)
Anorexia
85 (.42%)
Hypotension
85 (.42%)
Alopecia
80 (.4%)
Metastases To Central Nervous Syste...
78 (.39%)
Dizziness
77 (.38%)
Pain
77 (.38%)
Drug Interaction
76 (.38%)
Abdominal Pain
74 (.37%)
Acne
73 (.36%)
Fall
73 (.36%)
Lung Neoplasm Malignant
73 (.36%)
Skin Exfoliation
73 (.36%)
Constipation
72 (.36%)
Epistaxis
72 (.36%)
Incorrect Dose Administered
72 (.36%)
Confusional State
70 (.35%)
Oedema Peripheral
70 (.35%)
Platelet Count Decreased
69 (.34%)
Condition Aggravated
68 (.34%)
Gastrointestinal Haemorrhage
68 (.34%)
Mucosal Inflammation
64 (.32%)
Headache
63 (.31%)
Urinary Tract Infection
61 (.3%)
Lung Disorder
60 (.3%)
Renal Failure Acute
60 (.3%)
Hypoxia
59 (.29%)
Malaise
59 (.29%)
Convulsion
58 (.29%)
Sepsis
58 (.29%)
Chest Pain
56 (.28%)
Drug Ineffective
54 (.27%)
Infection
52 (.26%)
Pericardial Effusion
52 (.26%)
Back Pain
51 (.25%)
Aspartate Aminotransferase Increase...
50 (.25%)
Erythema
50 (.25%)
Eye Irritation
50 (.25%)
Blood Bilirubin Increased
49 (.24%)
Neoplasm Progression
49 (.24%)
Alanine Aminotransferase Increased
48 (.24%)
Haemorrhage
48 (.24%)
Renal Failure
48 (.24%)
International Normalised Ratio Incr...
47 (.23%)
White Blood Cell Count Decreased
47 (.23%)
Atrial Fibrillation
46 (.23%)
Conjunctivitis
46 (.23%)
Deep Vein Thrombosis
46 (.23%)
Skin Fissures
46 (.23%)
Arthralgia
44 (.22%)
Hyponatraemia
44 (.22%)
Pulmonary Oedema
44 (.22%)
Cerebrovascular Accident
42 (.21%)
Hypokalaemia
42 (.21%)
Non-small Cell Lung Cancer
42 (.21%)
Dysgeusia
39 (.19%)
Hypertension
39 (.19%)
Pneumonitis
39 (.19%)
Vision Blurred
39 (.19%)
Blood Alkaline Phosphatase Increase...
38 (.19%)
Pain In Extremity
38 (.19%)
Gait Disturbance
37 (.18%)
Dyspepsia
36 (.18%)
Muscular Weakness
36 (.18%)
Rash Pruritic
36 (.18%)
Rash Pustular
36 (.18%)
Chills
35 (.17%)
Hepatic Function Abnormal
34 (.17%)
Abdominal Distension
33 (.16%)
Deafness
33 (.16%)
Disseminated Intravascular Coagulat...
33 (.16%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Tarceva, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tarceva is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tarceva

What are the most common Tarceva adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tarceva, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tarceva is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Tarceva According to Those Reporting Adverse Events

Why are people taking Tarceva, according to those reporting adverse events to the FDA?

Non-small Cell Lung Cancer
1429
Product Used For Unknown Indication
1401
Lung Neoplasm Malignant
901
Pancreatic Carcinoma
314
Lung Adenocarcinoma
259
Lung Carcinoma Cell Type Unspecifie...
98
Show More Show More
Drug Use For Unknown Indication
75
Lung Cancer Metastatic
63
Pancreatic Carcinoma Metastatic
50
Bronchial Carcinoma
50
Hepatic Neoplasm Malignant
47
Non-small Cell Lung Cancer Metastat...
47
Neoplasm Malignant
47
Lung Squamous Cell Carcinoma Stage ...
43
Breast Cancer
39
Renal Cell Carcinoma Stage Unspecif...
38
Adenocarcinoma
35
Breast Cancer Metastatic
33
Prostate Cancer
32
Non-small Cell Lung Cancer Stage Iv
28
Lung Carcinoma Cell Type Unspecifie...
28
Lung Adenocarcinoma Metastatic
22
Squamous Cell Carcinoma
22
Renal Cell Carcinoma
21
Bile Duct Cancer
20
Glioblastoma Multiforme
20
Adenocarcinoma Pancreas
16
Metastatic Bronchial Carcinoma
15
Bronchioloalveolar Carcinoma
14
Metastases To Lung
13
Neoplasm
13
Tongue Neoplasm Malignant Stage Uns...
11
Ovarian Cancer
11
Metastases To Central Nervous Syste...
9
Lung Adenocarcinoma Stage Iv
9
Lung Neoplasm
9
Metastatic Neoplasm
8
Large Cell Carcinoma Of The Respira...
7
Gastric Cancer
7
Small Cell Lung Cancer Stage Unspec...
7
Non-small Cell Lung Cancer Stage Ii...
7
Laryngeal Cancer
7
Metastatic Squamous Cell Carcinoma
7
Lung Adenocarcinoma Recurrent
7
Chemotherapy
6
Lung Squamous Cell Carcinoma Stage ...
6
Oesophageal Carcinoma
6
Malignant Respiratory Tract Neoplas...
6
Lung Adenocarcinoma Stage Iii
6
Rectal Cancer Metastatic
6
Unevaluable Event
6

Drug Labels

LabelLabelerEffective
TarcevaPhysicians Total Care, Inc.05-JAN-12
TarcevaGenentech, Inc.30-OCT-12

Tarceva Case Reports

What Tarceva safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Tarceva. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Tarceva.